The FDA cleared the world’s smallest durable insulin delivery system, the Tandem Mobi powered by Control-IQ Technology. Full commercial availability is expected in early 2024. (Drug Delivery Business News)
Medtronic announced its MiniMed 780G insulin delivery system is now covered for all eligible Medicare and Medicare Advantage beneficiaries with type 1 diabetes.
The North American Menopause Society revamped its name and logo and will now go by The Menopause Society.
Three years after surgery, gastric bypass was superior to sleeve gastrectomy in patients with type 2 diabetes and obesity for several outcomes, including weight loss, diabetes remission, reflux, and more. (The Lancet Diabetes & Endocrinology)
The European Medicines Agency is investigating weight loss and diabetes drugs semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) over reports of suicidal thoughts.
And pharmacy claims data showed most patients prescribed popular weight-loss drugs like semaglutide discontinued them within a year. (Reuters)
Meanwhile, biotech companies are working to develop effective weight-loss drugs to work without nausea, a common side effect of the GLP-1 receptor agonist class. (Reuters)
More so than some lifestyle risk factors, loneliness was an even stronger predictor of cardiovascular disease in people with diabetes. (European Heart Journal)
Experiencing greater racial discrimination was linked with having a higher BMI and waist circumference in 10-year-old kids. (JAMA Network Open)
The FDA withdrew approval for Gemini Laboratories’ anabolic steroid oxandrolone (Oxandrin), once indicated for osteoporosis-related bone pain, citing multiple safety precautions and warnings over many years. (Endpoints News)
If you want to lose weight, which is better: time-restricted eating or calorie restriction? Actually, both work equally well, investigators found. (Annals of Internal Medicine)
![author['full_name']](https://clf1.medpagetoday.com/media/images/author/kristenMonaco_188.jpg)
Please enable JavaScript to view the